Pigmented villonodular synovitis, commonly abbreviated as PVNS, is a rare tumor that grows in the lining of joints, tendon sheaths, or bursae, causing swelling, pain, and progressive joint damage if untreated. Despite its intimidating name, PVNS is almost always benign, though “benign” undersells the havoc it can cause: the tumor erodes cartilage and bone, comes back after surgery at frustratingly high rates, and can leave people with lasting disability. The condition is now formally classified under the umbrella term tenosynovial giant cell tumor (TGCT), reflecting a shift in how researchers understand its biology, but most patients and many clinicians still use the older name.
What PVNS Actually Is
For decades, doctors treated PVNS as an inflammatory condition, something like an overactive immune reaction inside a joint. That understanding has been replaced. PVNS is now recognized as a clonal neoplastic proliferation, meaning it starts from a small group of cells that acquire a genetic change and begin growing abnormally.1PubMed Central. Pigmented Villonodular Synovitis: A Critical Review The World Health Organization reclassified it under the name tenosynovial giant cell tumor to reflect this, grouping together what used to be called PVNS (when it occurred inside a joint) and giant cell tumor of the tendon sheath (when it grew along a tendon outside a joint).2PubMed. Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis)
The tumor gets its distinctive brown or rust-colored appearance from hemosiderin, an iron-storage compound deposited by blood that leaks into the joint. Under a microscope, the tissue is a mix of mononuclear cells (the actual tumor-driving population) and large multinucleated giant cells that behave like osteoclasts, the same type of cell that normally breaks down bone. That osteoclast-like activity is one reason PVNS can eat into bone and cartilage over time.3PubMed Central. Multinucleated cells in pigmented villonodular synovitis and giant cell tumor of tendon sheath express features of osteoclasts
The Genetic Glitch Behind the Growth
The key molecular event in most cases of PVNS is a chromosomal translocation that fuses the CSF1 gene to a partner gene called COL6A3.4Proceedings of the National Academy of Sciences of the United States of America. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells CSF1 encodes a signaling protein called colony-stimulating factor 1. When the translocation occurs, even in a small fraction of the tumor cells, those cells begin pumping out CSF1 in large quantities. CSF1 acts as a powerful attractant for macrophages, which carry the matching receptor (CSF1R) on their surface. These macrophages flood into the joint lining, multiply, and ultimately make up the bulk of the tumor mass.5Current opinion in oncology. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis
So the tumor’s trick is essentially a bait-and-switch: a handful of genetically altered cells recruit a massive crowd of normal immune cells, and together they form a destructive mass. Single-cell analysis has identified a specific population of fibroblasts within the PVNS tissue that both express CSF1 and secrete another chemokine, CXCL12, which further accelerates macrophage migration into the area.6bioRxiv. Single-cell RNA-seq analysis reveals aberrant CSF1 expression in disease-causing synovial fibroblasts of pigmented villonodular synovitis Once recruited, macrophages polarize toward a tissue-remodeling state that promotes the inflammatory, joint-damaging environment characteristic of PVNS.7Cancer Treatment Reviews. Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis
Localized Versus Diffuse Disease
PVNS comes in two main forms, and the distinction matters enormously for treatment and prognosis. Localized PVNS is a discrete, well-defined nodule, often pedunculated like a small mushroom hanging from the synovial lining. Diffuse PVNS involves widespread thickening of the entire synovial membrane, sometimes engulfing the whole joint. The two forms rarely coexist in the same joint.8PubMed Central. Combined type of nodular and diffuse forms of pigmented villonodular synovitis in a single knee joint of a child
In a large UK series of 214 knee cases, roughly half were localized and half diffuse. The average patient was 39 years old and slightly more likely to be female. The two forms diverged sharply in recurrence: after surgery, the diffuse type came back in about 48% of cases, compared with under 9% for the localized form.9PubMed. Pigmented villonodular synovitis of the knee: A retrospective analysis of 214 cases at a UK tertiary referral centre This pattern is consistent across studies. Localized PVNS has reported recurrence rates of 0% to 15%, while diffuse PVNS recurs at rates ranging from 9% to 46%, depending on the series and how aggressively the surgery removed the tissue.10PubMed Central. Recurrence of pigmented villonodular synovitis of the knee: a case report with review of literature on the risk factors causing recurrence
The knee is the most commonly affected joint, accounting for the majority of cases. Hips, ankles, shoulders, and smaller joints of the hands and feet can also be involved, though less frequently. Joint anatomy affects the type of damage the tumor causes. In the knee, repeated surgeries for recurrences tend to drive progressive osteoarthritis. In tighter joints like the hip, ankle, and foot, bone erosion and cyst formation tend to appear earlier, likely because there is less room for the tumor to grow before it contacts bone.11The Journal of Rheumatology. Osteochondral Destruction in Pigmented Villonodular Synovitis During the Clinical Course
How PVNS Gets Diagnosed
Pain is the symptom that usually drives patients to seek care, sometimes accompanied by swelling, stiffness, and reduced range of motion. A palpable mass is less common in PVNS than in some other synovial conditions.12PubMed Central. Clinical comparison of tenosynovial giant cell tumors, synovial chondromatosis, and synovial sarcoma: analysis and report of 53 cases Because PVNS is rare and mimics more common problems like meniscal tears, rheumatoid arthritis, or chronic synovitis, misdiagnosis and diagnostic delay are extremely common. Many patients go months or years before the condition is identified.
MRI is the imaging workhorse for PVNS, and in experienced hands, the findings are distinctive enough to be nearly diagnostic on their own. The hemosiderin deposits within the tumor create prominent low signal intensity on T2-weighted images and a characteristic “blooming” artifact on gradient-echo sequences.13PubMed. Pigmented villonodular synovitis: radiologic-pathologic correlation These dark patches reflect the iron content and help distinguish PVNS from other causes of joint swelling that do not deposit hemosiderin. A tissue biopsy remains the gold standard for confirming the diagnosis, but the MRI appearance is often distinctive enough to guide surgical planning even before biopsy results are in.
Surgery and the Recurrence Problem
Surgery is the first-line treatment for PVNS. For localized disease, excision of the nodule typically resolves the problem, with low recurrence risk and good functional outcomes. Diffuse disease is a different story. The tumor spreads throughout the synovial lining, and achieving complete removal is difficult.
The debate in diffuse knee PVNS has long centered on open surgery versus arthroscopic approaches. Open synovectomy tends to produce lower recurrence rates. One study found recurrence-free survival of 95% for open surgery versus 62% for arthroscopic at two years, dropping to 71% and 41%, respectively, at five years.14PubMed Central. Outcomes after excision of pigmented villonodular synovitis of the knee A systematic review confirmed this pattern, concluding that recurrence is mainly driven by how completely the initial lesion is removed, which tends to be better with an open technique.15PubMed Central. Open versus arthroscopic surgery for diffuse tenosynovial giant-cell tumours of the knee: a systematic review
The trade-off is that arthroscopic surgery is easier on the patient in the short term: less operative time, less bleeding, shorter hospital stays, and better functional scores in the first few years after surgery.16PubMed. A comparison of open and arthroscopic surgery for treatment of diffuse pigmented villonodular synovitis of the knee Some surgeons try to combine approaches, using arthroscopy for portions of the joint that are easily accessible and an open incision for areas behind the knee or other hard-to-reach spots. Adding adjuvant treatment after surgery, whether external beam radiation or intra-articular injection of radioactive yttrium-90, has been associated with better outcomes in extensive diffuse disease.17Rheumatology. The use of surgery and yttrium 90 in the management of extensive and diffuse pigmented villonodular synovitis of large joints
Across a large multi-center study of 294 patients treated before targeted drugs became available, overall local failure was reported in 28% of cases: 36% for diffuse disease, 14% for localized. The median time to recurrence was about 16 months, which means most failures show up relatively early in follow-up.18PubMed. Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors
Drugs That Target the Root Cause
Understanding the CSF1/CSF1R signaling axis opened the door to targeted therapy. If the tumor grows by broadcasting CSF1 to attract macrophages, blocking the receptor those macrophages use to detect CSF1 should shrink the tumor. That is exactly what CSF1R inhibitors do.
Pexidartinib was the first drug approved for PVNS/TGCT, gaining FDA approval in 2019 based on the ENLIVEN trial. In that randomized study, 39% of patients on pexidartinib achieved an objective tumor response by standard imaging criteria at 25 weeks, compared with 0% on placebo.19The Lancet. Pexidartinib versus placebo for advanced tenosynovial giant-cell tumour (ENLIVEN): a randomised phase 3 trial Patients also reported meaningful improvements in symptoms and daily function. However, pexidartinib comes with a significant liver safety concern. In the combined safety dataset, 95% of treated patients experienced some form of hepatic adverse reaction, though the vast majority were mild, reversible elevations in liver enzymes. About 4% of patients developed serious mixed or cholestatic liver injury requiring them to stop the drug, and rare cases have been severe enough to necessitate liver transplantation.20PubMed Central. Pexidartinib Long‐Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors Because of this risk, pexidartinib carries an FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) requiring liver monitoring.
In February 2025, the FDA approved vimseltinib as the second CSF1R inhibitor for TGCT. Vimseltinib was designed to be more selective for CSF1R, avoiding some of the off-target activity that contributes to pexidartinib’s liver toxicity.21PubMed Central. Vimseltinib: A novel colony stimulating factor 1 receptor (CSF1R) inhibitor approved for treatment of tenosynovial giant cell tumors (TGCTs) In the phase 3 MOTION trial, vimseltinib achieved a 40% objective response rate at week 25, again compared with 0% for placebo. When measured by tumor volume score, a more sensitive metric, the response rate was 67%. Most side effects were mild; the only grade 3 or 4 adverse event occurring in more than 5% of patients was elevated blood creatine phosphokinase. Critically, no cholestatic hepatotoxicity or drug-induced liver injury was observed.22The Lancet. Efficacy and safety of vimseltinib in advanced tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Both drugs are indicated for patients whose disease is not easily managed by surgery or for whom surgery would likely cause serious functional problems or complications.
Living with PVNS and Its Aftermath
Although PVNS is not life-threatening in the vast majority of cases, the toll on daily life is real. Pain, swelling, stiffness, and reduced range of motion are hallmark symptoms that affect physical function and overall well-being.23PubMed. Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts Registry data show that these symptoms are the most common and critical complaints reported by patients, particularly in diffuse disease affecting large joints.24The Oncologist. Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment Strategies
The good news is that surgery, when successful, does restore quality of life. A study measuring patient-reported outcomes found that before surgery and in the immediate postoperative period, quality-of-life scores were meaningfully worse than the general population. But by three to six months, scores improved to population norms and remained stable for years afterward. For patients with diffuse disease in the knee, functional scores showed sustained, clinically meaningful improvement from six months out to at least five years.25PubMed. The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function
The economic burden, however, adds up. In the United States, patients with TGCT have roughly 2.8 times the rate of inpatient admissions, 2.2 times the outpatient visits, and 2.6 times the work-loss days compared with matched controls. Total annual healthcare and work-loss costs run about $12,000 higher than for similar individuals without the disease.26PubMed. The Economic Burden of Tenosynovial Giant Cell Tumors Among Employed Workforce in the United States European data tell a similar story, with surgery accounting for about 70% of total healthcare costs.27PubMed Central. Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry For a disease that primarily strikes working-age adults, those costs accumulate over years of treatment, surveillance imaging, and occasionally multiple surgeries.
When PVNS Turns Dangerous
True malignant transformation of PVNS is exceedingly rare, with only about 30 to 40 cases reported in the medical literature. When it does occur, the prognosis is grim: published mortality rates fall between 33% and 50%, with a median survival of roughly 21 months after diagnosis. There is also a separate, even rarer entity called metastasizing benign TGCT, where the tumor spreads to distant sites like the lungs despite appearing histologically benign. Based on a very small number of reported cases, the benign-appearing metastatic form seems to carry a much more favorable outlook than the truly malignant version, with patients remaining asymptomatic at two-year follow-up.28Radiology Case Reports. Histologically benign metastasizing tenosynovial giant cell tumor mimicking metastatic malignancy: A case report and review of literature
Neither scenario should cause outsized anxiety for a typical patient. The overwhelming majority of PVNS cases remain benign throughout their course. But the existence of rare malignant variants underscores why long-term surveillance after treatment matters, particularly for patients with diffuse disease or multiple recurrences.
PVNS in Animals
Humans are not the only species that develops PVNS. The condition has been documented, albeit rarely, in dogs. One published case described bilateral villonodular synovitis in a dog, confirmed by biopsy as chronic active villonodular synovitis.29PubMed. Bilateral pigmented villonodular synovitis in a dog A separate report documented a tarsal giant cell tumor of the tendon sheath in a dog, noting that the findings were consistent with pigmented villonodular tenosynovitis and that the condition affects multiple animal species.30Ciência Rural. Tarsal villonodular tenosynovitis (giant cell tumor of tendon sheath) in a dog The rarity in veterinary medicine mirrors the rarity in humans, and the histological features are strikingly similar across species. Whether the same CSF1-driven mechanism operates in animal cases has not been well studied, but the shared pathology suggests the fundamental biology of synovial overgrowth is deeply conserved.